Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ...

Ulcerative colitis is a chronic disease with recurrent symptoms and significant morbidity. The precise etiology is still unknown. As many as 25 percent of patients with ulcerative colitis have ...

Ulcerative colitis can cause symptoms like bloody stool, diarrhea, and fatigue. Family history, age, and ethnicity are ...

New treatments are in development for inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. Find out what ...

The disease is characterized by repeated cycles of active phases, when symptoms worsen, and remission phases, when symptoms ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic inflammatory disease of the large intestine. While treatments for the disease ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Ottawa, May 09, 2024 (GLOBE NEWSWIRE) -- The global ulcerative colitis treatment market size was valued at USD 10.16 billion in 2023 and is predicted to hit around USD 13.81 billion by 2032, a study ...

A peer-reviewed study associated elevated circulating B cells before treatment with increased risk of immune checkpoint ...

A Mendelian randomization and transcriptomic study identified 11 gut microbial taxa genetically associated with ulcerative ...